On the move: Healx gets new director of digital chemistry

AI-focused health tech firm Healx has appointed leading computational drug discovery expert, Nathan Brown, as director of digital chemistry.

Nathan joins from BenevolentAI, where he led the Cheminformatics team and was responsible for the research and development of new and effective approaches for computational drug design.

Globally recognised as a thought-leader in cheminformatics and computational drug discovery, Nathan is the inventor of the first multi-objective *de novo* molecular design system and has published over 50 papers and four books on the field.

A Fellow of The Royal Society of Chemistry, he is also the 2017 recipient of the Corwin Hansch Award – an award given by the Hansch-Fujita Foundation each year to a scholar under the age of 40 for significant contributions to the field of computer-aided drug design.

Prior to his work at BenevolentAI, Nathan was Head of In Silico Medicinal Chemistry at The Institute of Cancer Research in London where he founded and led the In Silico Medicinal Chemistry team for over ten years. He was also a Presidential Research Fellow at the Novartis Institutes for BioMedical Research.

Commenting on his appointment, Nathan Brown said: “I’m delighted to be joining Healx at what is an exciting time for the growth of the company. I’m really looking forward to working with the diverse talent at Healx and continuing to build a terrific capability in digital chemistry applied to cutting edge AI and data-driven drug discovery.”